Activated factor XI–antithrombin and thrombin–antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non–small-cell lung cancer

This publication has 51 references indexed in Scilit:

• Prevalence of Thromboembolic Events in Patients With Non–Small Cell Lung Cancer and RET Fusions
  JAMA Oncology, 2023
• Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study
  Cancer Immunology, Immunotherapy, 2023
• Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
  Annals of Oncology, 2023
• Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data
  International Journal of Clinical Oncology, 2022
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty
  JAMA, 2020
• Prognostic and predictive value of plasma d-dimer levels in patients with small-cell lung cancer
  International Journal of Clinical Oncology, 2018
• The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2017
• Mechanisms and risk factors of thrombosis in cancer
  Critical Reviews in Oncology/Hematology, 2017
• Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients
  Clinical Lung Cancer, 2012
• A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score
  Internal and Emergency Medicine, 2012